AzTrials
AzTrials

AKINCT07477652

What is the Effect of Acute Kidney Injury on Weaning From Mechanical Ventilation in Critically Ill Adult Patients?

An observational study of AKI and Critical Illness, run by Assiut University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

The aim of this study is to evaluate the impact of acute kidney injury (AKI) on the success rate, duration, and complications of weaning from mechanical ventilation in critically ill adult patients admitted to the intensive care unit (ICU), and to identify whether AKI is an independent predictor of difficult, failed… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
AKI, Critical Illness
What is being tested?
Acute Kidney Injury (AKI) Exposure
How many people
85 participants
Where
No sites listed yet
Study dates
1 Apr 2026to 1 Jul 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Critically ill patients 18 years or above with acute kidney injury.

Who may be able to join

  • • Age ≥ 18 years of either sex.
  • Admission to the ICU and receiving invasive mechanical ventilation via endotracheal tube.
  • Expected duration of mechanical ventilation ≥ 24 hours.
  • Hemodynamically stable or stabilized at the time of first spontaneous breathing trial (SBT) according to unit protocol (e.g., mean arterial pressure ≥ 65 mmHg with or without low dose vasopressors).
  • Availability of baseline and daily serum creatinine, urine output, and relevant clinical data to diagnose and stage acute kidney injury according to KDIGO criteria.

Who cannot join

  • Pre existing end stage renal disease on chronic dialysis (hemodialysis or peritoneal dialysis).
  • Known advanced chronic kidney disease (e.g., baseline estimated GFR < 30 mL/min/1.73 m²) if baseline creatinine is available.
  • Previous tracheostomy before current ICU admission.
  • Neuromuscular diseases or spinal cord injury causing chronic ventilatory dependence.
  • Severe pre existing cognitive impairment or brain death at ICU admission.
  • Do not intubate or comfort care only orders at time of eligibility assessment.
  • Re intubation after ICU discharge (only the first ICU admission episode will be considered).
  • Patients or legal representatives refusing or withdrawing consent

About this study

Official title: Effect of Acute Kidney Injury on Weaning From Mechanical Ventilation in Critically Ill Adult Patients

The aim of this study is to evaluate the impact of acute kidney injury (AKI) on the success rate, duration, and complications of weaning from mechanical ventilation in critically ill adult patients admitted to the intensive care unit (ICU), and to identify whether AKI is an independent predictor of difficult, failed or complicated or weaning.

Read the detailed description

Acute kidney injury (AKI) is a frequent and serious complication in critically ill patients receiving invasive mechanical ventilation, affecting up to onethird of ICU admissions and contributing substantially to morbidity and mortality(1,2). AKI is associated with prolonged organ dysfunction, increased length of ICU stay, higher healthcare costs, and poorer overall outcomes, particularly in patients who require respiratory support.

Mechanical ventilation itself can influence renal perfusion and function through hemodynamic alterations, intrathoracic pressure changes, and activation of neurohormonal and inflammatory pathways. Positive endexpiratory pressure (PEEP) and large tidal volumes may reduce renal blood flow and glomerular filtration rate, thereby increasing the risk of AKI in ventilated patients. Conversely, AKI can aggravate pulmonary dysfunction by promoting fluid overload, interstitial edema, and systemic inflammation, which may impair gas exchange and respiratory muscle performance.

Several clinical studies have demonstrated that AKI is associated with prolonged duration of mechanical ventilation and higher rates of difficult or prolonged weaning. One observational cohort of mechanically ventilated ICU patients showed that AKI was an independent predictor of prolonged mechanical ventilation exceeding 21 days, even after adjusting for disease severity. In another study focusing on cancer patients, AKI was linked to significantly longer weaning duration, higher weaningfailure rates, and increased ICU mortality.

In patients with chronic obstructive pulmonary disease (COPD) and respiratory failure, AKI occurring within the first 48 hours of ICU admission has been shown to reduce glomerular filtration rate, increase the use of PEEP and ventilatory support, prolong mechanical ventilation, and decrease weaning success. These patients with AKI also had higher APACHE II scores, more days in the ICU, and greater likelihood of difficult weaning or death compared with nonAKI counterparts. Fluid overload and oliguria related to AKI likely contribute to positive net fluid balance, which in turn worsens pulmonary congestion and respiratory mechanics and may delay successful liberation from the ventilator.

The bidirectional "kidney-lung" interaction means that pulmonary injury can precipitate AKI and vice versa, creating a vicious cycle that complicates criticalcare management. Mechanical ventilationinduced AKI has been associated with worse respiratory system mechanics and higher levels of inflammatory biomarkers, further impairing cardiorespiratory reserve and weaning potential. Despite these associations, the exact mechanisms by which AKI affects weaning outcomes, such as diaphragmatic dysfunction, systemic inflammation, or drug accumulation, remain incompletely elucidated.

Given the high prevalence of AKI among mechanically ventilated patients and its potential to prolong ICU stay, increase mortality, and hinder successful weaning, a focused investigation is needed to clarify the independent contribution of AKI to weaning failure and prolonged ventilation. Understanding this relationship may help refine risk stratification, optimize renal protective ventilation strategies, guide fluid management, and ultimately improve weaning protocols and patient outcomes.

The rationale for this study is to determine whether AKI is an independent factor influencing weaning success and duration from mechanical ventilation in critically ill adults, and to provide evidence based data that can inform early identification of highrisk patients and guide tailored interventions to facilitate earlier and safer liberation from the ventilator.

Being tested
Acute Kidney Injury (AKI) Exposure
Medical subject headings
Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Acute Kidney Injury (AKI) ExposureOther

    Participants will be categorized according to the presence or absence of Acute Kidney Injury during their ICU stay. All patients will undergo standard management of Mechanical Ventilation and routine weaning protocols as per ICU practice. The study will evaluate the association between AKI and outcomes of Weaning from Mechanical Ventilation, including success rate, duration, and complications.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Weaning success rate

    Weaning from mechanical ventilation success: defined as extubation with no need for reintubation or invasive mechanical ventilation within 48-72 hours (use the definition adopted by your ICU).

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Mar 2026
  2. Study start1 Apr 2026 (estimated)
  3. Primary completion1 Apr 2027 (estimated)
  4. Study completion1 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
85 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07477652
Sponsor's protocol ID
AKI and Critically ill patiens
Status last verified
Mar 2026
First submitted
13 Mar 2026
Last updated
17 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of AKI and Critical Illness, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Weaning success rate (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in